-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK-backed ViiV says phase IIIb CROWN trial shows Cabenuva beats daily oral HIV therapy in viral suppression

PUBT·10/06/2026 13:02:36
Listen to the news
GSK-backed ViiV says phase IIIb CROWN trial shows Cabenuva beats daily oral HIV therapy in viral suppression
  • GSK-backed ViiV reported a Phase IIIb CROWN trial success for long-acting Cabenuva in people with unsuppressed HIV at entry.
  • The study showed better viral suppression than standard daily oral therapy, supporting potential use in patients who struggle on pills.
  • Use in people with detectable virus remains investigational, with data slated for submission to regulators for review.
  • Full results have not yet been presented; the companies plan to disclose them at an upcoming scientific meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610060900BIZWIRE_USPR_____20260930_BW402828) on October 06, 2026, and is solely responsible for the information contained therein.